Clinical Research Details Clinical Research AMG 423 20110203: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects with Chronic Heart Failure with Reduced Ejection Fraction Study Description To evaluate the effect of treatment with omecamtiv mecarbil (OM) compared with placebo on the time to cardiovascular (CV) death or first HF event, whichever occurs first, in subjects with chronic HF with reduced ejection fraction (HFrEF) receiving standard of care (SoC) therapy Subjects will be randomized to study drug or placebo. Investigators Francesco Franchi, M.B.Ch.B. (M.D.) Medicine Fabiana Rollini, M.B.Ch.B. (M.D.) Medicine